Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Ferrum Resources Limited ("Ferrum") Update

24 Aug 2011 16:16

RNS Number : 9792M
Emerging Metals Limited
24 August 2011
 



For Immediate Release: 24 August 2011

 

Emerging Metals Limited

("EML" or the "Company")

 

Ferrum Resources Limited ("Ferrum") Update

 

The Company is pleased to provide an update on its due diligence into Ferrum, its 37.23 per cent associate company and in particular the obligations of Ferrum in respect of its exploration rights in Sierra Leone, Guinea and Cameroon.

 

As announced on 7 June 2011, the US$13.5 million paid by Ferrum for its 63.53 per cent. interest in CMC Guernsey Limited (which indirectly holds a 95 per cent. interest in six iron ore exploration licences in Cameroon), together with an additional US$1.5 million in cash subscriptions received by CMC Guernsey Limited, will be applied initially towards a high resolution aero-mag survey of the licence areas and thereafter as CMC Guernsey Limited judges warranted after that survey. It is believed that the gross proceeds of US$15 million raised by CMC Guernsey Limited will fully fund its initial exploration programme for the six licences.

 

In Sierra Leone and Guinea, Ferrum also intends to conduct aero-mag surveys on its licence areas, as well as additional geological and reconnaissance mapping. Ferrum has estimated these two work programmes, including in country operating and capital costs and consultants, will cost in aggregate approximately US$2.5 million over the next six months. It is necessary for Ferrum to commence these work programmes to maintain its rights to the licence areas in good standing which it believes are highly valuable.

 

Given current market conditions, the Company has determined that it will presently not exercise its option to acquire the 62.77 per cent. of issued Ferrum shares which it does not already own. The Company is meanwhile exploring options to fund Ferrum's short term cash requirements. It is currently expected that this will involve a placing by way of new ordinary shares in the Company to parties including certain directors. A further announcement in this regard will be made in due course.

 

-Ends-

 

For further information

 

Emerging Metals Limited

Religare Capital Markets (UK) Limited

Evolution Securities Limited

GTH Communications

Denham Eke

Peter Trevelyan-Clark

Emily Staples

 

Romil Patel

Tim Redfern

Toby Hall

Christian Pickel

+44 (0) 1624 639396

+44 (0) 20 7444 0800

+44 (0)20 7071 4300

+44 (0) 20 3103 3902

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRUSAVRAVAWUAR
Date   Source Headline
19th May 20238:00 amRNSADS Program collapse
15th May 20237:00 amRNSChange of Record Time and Last Day of Dealings
11th May 202312:00 pmRNSWebull Corporate Communications Service Platform
11th May 20237:00 amRNSChange of Delisting Date to 22 May 2023
3rd May 20231:00 pmRNSResult of Meeting
3rd May 20237:00 amRNSPresentation on OK-101 at ASCRS
2nd May 20237:00 amRNSFirst-Patient First-Visit for Phase 2 Trial
25th Apr 20237:00 amRNSActivation of First Clinical Trial Site in the U.S
5th Apr 20237:00 amRNSNOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION
4th Apr 20237:00 amRNSNotice Of Intention To Delist From The LSE
30th Mar 20237:00 amRNSDirector Acquires Shares
29th Mar 20237:00 amRNSDirector acquires shares
24th Mar 20237:00 amRNSDirector/PDMR Shareholding
16th Mar 20237:01 amRNSListing of Trial on the ClinicalTrials.gov Website
16th Mar 20237:00 amRNSClosing of Global Private Placement
15th Mar 20237:01 amRNSDirector/PDMR Dealings
14th Mar 20237:00 amRNSIssue of Equity
13th Mar 20233:16 pmRNSCEO Interview
6th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSCustom Clearance of GMP Packaged OK-101 Drug
23rd Feb 20237:00 amRNSAppointment to Scientific Advisory Board
21st Feb 20237:00 amRNSCorporate Presentation
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20232:05 pmRNSSecond Price Monitoring Extn
20th Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 202311:05 amRNSSecond Price Monitoring Extn
20th Feb 202311:00 amRNSPrice Monitoring Extension
20th Feb 20239:05 amRNSSecond Price Monitoring Extn
20th Feb 20239:00 amRNSPrice Monitoring Extension
17th Feb 20234:40 pmRNSSecond Price Monitoring Extn
17th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSAllotment of Shares and Total Voting Rights
10th Jan 20234:40 pmRNSSecond Price Monitoring Extn
10th Jan 20234:35 pmRNSPrice Monitoring Extension
10th Jan 20232:05 pmRNSSecond Price Monitoring Extn
10th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 20231:15 pmRNSInterim Results - availability
30th Dec 20227:00 amRNSInterim Results for the Six Months Ending 30Sept22
22nd Dec 20227:00 amRNSU.S. FDA Clearance of IND Application for OK-101
21st Dec 20227:00 amRNSOKYO to Participate at Biotech Showcase
6th Dec 20227:00 amRNSOKYO files a registration statement with the SEC
1st Dec 20227:00 amRNSChange of Auditor
24th Nov 20227:00 amRNSDirector/PDMR Shareholding
21st Nov 20227:00 amRNSU.S. IND Filing on OK-101 for the Treatment of DED
20th Oct 20227:00 amRNSOKYO to participate at 2022 ThinkEquity Conference
8th Sep 20222:30 pmRNSOKYO interview on Bloomberg: RedChip Money Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.